MANP in Hypertension With Metabolic Syndrome: Proof-of-Concept Study of Natriuretic Peptide-Based Therapy for Cardiometabolic Disease

Xiao Ma; Paul M. McKie; Seethalakshmi R. Iyer; Christopher Scott; Kent Bailey; Bradley K. Johnson; Sherry L. Benike; Horng Chen; Wayne L. Miller; Aderville Cabassi; John C. Burnett; Valentina Cannone

doi:10.1016/j.jacbts.2023.08.011

MANP in Hypertension With Metabolic Syndrome: Proof-of-Concept Study of Natriuretic Peptide-Based Therapy for Cardiometabolic Disease

Xiao Ma, Paul M. McKie, Seethalakshmi R. Iyer, Christopher Scott, Kent Bailey, Bradley K. Johnson, Sherry L. Benike, Horng Chen, Wayne L. Miller, Aderville Cabassi, John C. Burnett, Valentina Cannone

Research output: Contribution to journal › Article › peer-review

Abstract

Hypertension and metabolic syndrome frequently coexist to increase the risk for adverse cardiometabolic outcomes. To date, no drug has been proven to be effective in treating hypertension with metabolic syndrome. M-atrial natriuretic peptide is a novel atrial natriuretic peptide analog that activates the particulate guanylyl cyclase A receptor. This study conducted a double-blind, placebo-controlled trial in 22 patients and demonstrated that a single subcutaneous injection of M-atrial natriuretic peptide was safe, well-tolerated, and exerted pleiotropic properties including blood pressure–lowering, lipolytic, and insulin resistance–improving effects.

Original language	English (US)
Pages (from-to)	18-29
Number of pages	12
Journal	JACC: Basic to Translational Science
Volume	9
Issue number	1
DOIs	https://doi.org/10.1016/j.jacbts.2023.08.011
State	Published - Jan 2024

Keywords

M-atrial natriuretic peptide
MANP
MetS
NEFA
cGMP
cyclic guanosine monophosphate
hypertension
insulin resistance
metabolic syndrome
nonesterified fatty acids

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jacbts.2023.08.011

Cite this

Ma, X., McKie, P. M., Iyer, S. R., Scott, C., Bailey, K., Johnson, B. K., Benike, S. L., Chen, H., Miller, W. L., Cabassi, A., Burnett, J. C., & Cannone, V. (2024). MANP in Hypertension With Metabolic Syndrome: Proof-of-Concept Study of Natriuretic Peptide-Based Therapy for Cardiometabolic Disease. JACC: Basic to Translational Science, 9(1), 18-29. https://doi.org/10.1016/j.jacbts.2023.08.011

Ma, X, McKie, PM, Iyer, SR, Scott, C, Bailey, K, Johnson, BK, Benike, SL, Chen, H, Miller, WL, Cabassi, A, Burnett, JC & Cannone, V 2024, 'MANP in Hypertension With Metabolic Syndrome: Proof-of-Concept Study of Natriuretic Peptide-Based Therapy for Cardiometabolic Disease', JACC: Basic to Translational Science, vol. 9, no. 1, pp. 18-29. https://doi.org/10.1016/j.jacbts.2023.08.011

@article{4680f8910197471da212692e3d2a88ac,

title = "MANP in Hypertension With Metabolic Syndrome: Proof-of-Concept Study of Natriuretic Peptide-Based Therapy for Cardiometabolic Disease",

abstract = "Hypertension and metabolic syndrome frequently coexist to increase the risk for adverse cardiometabolic outcomes. To date, no drug has been proven to be effective in treating hypertension with metabolic syndrome. M-atrial natriuretic peptide is a novel atrial natriuretic peptide analog that activates the particulate guanylyl cyclase A receptor. This study conducted a double-blind, placebo-controlled trial in 22 patients and demonstrated that a single subcutaneous injection of M-atrial natriuretic peptide was safe, well-tolerated, and exerted pleiotropic properties including blood pressure–lowering, lipolytic, and insulin resistance–improving effects.",

keywords = "M-atrial natriuretic peptide, MANP, MetS, NEFA, cGMP, cyclic guanosine monophosphate, hypertension, insulin resistance, metabolic syndrome, nonesterified fatty acids",

author = "Xiao Ma and McKie, {Paul M.} and Iyer, {Seethalakshmi R.} and Christopher Scott and Kent Bailey and Johnson, {Bradley K.} and Benike, {Sherry L.} and Horng Chen and Miller, {Wayne L.} and Aderville Cabassi and Burnett, {John C.} and Valentina Cannone",

note = "Publisher Copyright: {\textcopyright} 2024 The Authors",

year = "2024",

month = jan,

doi = "10.1016/j.jacbts.2023.08.011",

language = "English (US)",

volume = "9",

pages = "18--29",

journal = "JACC: Basic to Translational Science",

issn = "2452-302X",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - MANP in Hypertension With Metabolic Syndrome

T2 - Proof-of-Concept Study of Natriuretic Peptide-Based Therapy for Cardiometabolic Disease

AU - Ma, Xiao

AU - McKie, Paul M.

AU - Iyer, Seethalakshmi R.

AU - Scott, Christopher

AU - Bailey, Kent

AU - Johnson, Bradley K.

AU - Benike, Sherry L.

AU - Chen, Horng

AU - Miller, Wayne L.

AU - Cabassi, Aderville

AU - Burnett, John C.

AU - Cannone, Valentina

PY - 2024/1

Y1 - 2024/1

N2 - Hypertension and metabolic syndrome frequently coexist to increase the risk for adverse cardiometabolic outcomes. To date, no drug has been proven to be effective in treating hypertension with metabolic syndrome. M-atrial natriuretic peptide is a novel atrial natriuretic peptide analog that activates the particulate guanylyl cyclase A receptor. This study conducted a double-blind, placebo-controlled trial in 22 patients and demonstrated that a single subcutaneous injection of M-atrial natriuretic peptide was safe, well-tolerated, and exerted pleiotropic properties including blood pressure–lowering, lipolytic, and insulin resistance–improving effects.

AB - Hypertension and metabolic syndrome frequently coexist to increase the risk for adverse cardiometabolic outcomes. To date, no drug has been proven to be effective in treating hypertension with metabolic syndrome. M-atrial natriuretic peptide is a novel atrial natriuretic peptide analog that activates the particulate guanylyl cyclase A receptor. This study conducted a double-blind, placebo-controlled trial in 22 patients and demonstrated that a single subcutaneous injection of M-atrial natriuretic peptide was safe, well-tolerated, and exerted pleiotropic properties including blood pressure–lowering, lipolytic, and insulin resistance–improving effects.

KW - M-atrial natriuretic peptide

KW - MANP

KW - MetS

KW - NEFA

KW - cGMP

KW - cyclic guanosine monophosphate

KW - hypertension

KW - insulin resistance

KW - metabolic syndrome

KW - nonesterified fatty acids

UR - http://www.scopus.com/inward/record.url?scp=85176944940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85176944940&partnerID=8YFLogxK

U2 - 10.1016/j.jacbts.2023.08.011

DO - 10.1016/j.jacbts.2023.08.011

M3 - Article

AN - SCOPUS:85176944940

SN - 2452-302X

VL - 9

SP - 18

EP - 29

JO - JACC: Basic to Translational Science

JF - JACC: Basic to Translational Science

IS - 1

ER -

MANP in Hypertension With Metabolic Syndrome: Proof-of-Concept Study of Natriuretic Peptide-Based Therapy for Cardiometabolic Disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this